A novel endotoxin antagonist attenuates tumor necrosis factor-α secretion

Peter S. Dahlberg, Robert D. Acton, Richard J. Battafarano, Marc E. Uknis, Craig A. Ratz, Jennifer W. Johnston, Judith R. Haseman, Beulah H. Gray, David L. Dunn

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Twenty-seven amino acid peptides with sequences corresponding to a proposed endotoxin binding region of bactericidal permeability increasing protein (BPI): 1) inhibit lipopolysaccharide induced macrophage tumor necrosis factor-α (TNF-α) secretion, 2) have bactericidal activity against gram-negative bacteria, and 3) protect mice from a lethal lipopolysaccharide (LPS) challenge. Unfortunately, peptides have a short half-life in vivo. Therefore, we have chemically conjugated the BPI based peptide, BG38, to a larger carrier protein, keyhole limpet hemocyanin (KLH), and characterized its ability: 1) to inhibit LPS induced macrophage TNF-α secretion and 2) to decrease plasma endotoxin and TNF-α levels following an i.v. injection of E. coli 0111:B4 LPS. BG38-KLH inhibited cultured macrophage TNF-α secretion in response to LPS derived from four pathogenic strains of gram-negative bacteria in a dose dependent manner (>90% inhibition at 50 μg/ml, P < 0.05 Student's t test). BG38-KLH also decreased serum endotoxin (>90%, P < 0.05 Student's t test) and peak TNF-α levels (>30% inhibition, P < 0.05 Student's t test) following E. coli LPS challenge in a murine gram-negative bacterial sepsis model. Novel endotoxin antagonists based upon a small domain of BPI represent promising reagents for the treatment of serious gram-negative bacterial infections.

Original languageEnglish (US)
Pages (from-to)44-48
Number of pages5
JournalJournal of Surgical Research
Issue number1
StatePublished - Jun 1996
Externally publishedYes

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'A novel endotoxin antagonist attenuates tumor necrosis factor-α secretion'. Together they form a unique fingerprint.

Cite this